(From the January 2014 Issue of PediatricsOnline)
We are working tirelessly to solve the puzzle of pediatric cancer. It is our hope that, by sharing highlights of our progress with our peers, we can collectively accelerate the discovery of powerful treatments and curative therapies. Please use this document as a brief review of our current research and clinical endeavors. We look forward to a future of growing possibilities, improved treatments and—with your collaboration—a world of hope for children with cancer and blood diseases.
Leading the Way in Pediatric Cancer Research
The Center for Childhood Cancer and Blood Diseases in The Research Institute at Nationwide Children’s, directed by Peter Houghton, PhD, coordinates the division’s research endeavors. Faculty focus areas include the biology and therapy of rhabdomyosarcoma and other childhood tumors; chemotherapy for childhood solid tumors; regulation of alternative pre-mRNA splicing; regulation and function of tumor suppressor genes; and oncolytic viral therapy in pediatric solid tumors. Approximately three-fourths of eligible oncology patients at Nationwide Children’s are enrolled in clinical research trials, placing us among the leading cancer centers for clinical trial enrollment in the Children’s Oncology Group.
Our program coordinates with the Biopathology Center at Nationwide Children’s, the largest pediatric cancer repository in the U.S., employing more than 150 people and processing over 1,000 samples per day.
About the Division of Hematology/Oncology/Blood and Marrow Transplantation (BMT)
We in the Division of Hematology/Oncology/BMT treat patients diagnosed with the full array of blood disorders, cancers, immune-deficiency disorders, bone marrow failure syndromes and inherited metabolic storage diseases. Conditions treated include leukemia/lymphoma, brain tumors, bone and soft tissue sarcomas, neuroblastoma, embryonal tumors of the kidney and liver, melanoma, rare tumors in patients of all ages, sickle cell diseases, bone marrow failures, bleeding disorders, hemostasis/thrombosis disorders, other disorders requiring stem cell transplantation and genetic disorders involving blood and/or cancer.
We are a member institution of the Children’s Oncology Group (COG) and the Therapeutic Advances for Childhood Leukemia (TACL) consortium. Our bone marrow transplant program is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT). We partner with The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, which includes our National Cancer Institute (NCI) Comprehensive Cancer Center designation. The division hosts more than six specialty programs and clinics and up to 10 fellows in pediatric hematology/oncology.